All articles
What is HRT for Menopause? Benefits & Risks
Reading time:
8 min
Menopause
Get expert guidance and a personalized care plan designed around you.
What Is Hormone Replacement Therapy (HRT)?
Hormone replacement therapy supplements the hormones your body stops producing after menopause. The goal of HRT is not to return hormone levels to what they were before menopause, but to help the body find a new balance that controls symptoms without excess health risk. While estrogen is the primary hormone replaced, the exact treatment depends on your individual needs.
Types of HRT
Combined Estrogen-Progesterone Therapy: Women with an intact uterus need both estrogen and progesterone (or progestin). Without progesterone to balance estrogen’s effects, the uterine lining thickens excessively, raising cancer risk.
Estrogen-Only Therapy: For patients who have had their uterus removed (hysterectomy), estrogen alone is typically prescribed since there’s no uterine lining to protect.
Not All Hormones Are Equal
Research shows important differences between hormone types. Estradiol, which is bioidentical to your body’s natural estrogen, has a better safety profile than conjugated equine estrogens, with lower risks for blood clots and metabolic issues.
The progesterone type also matters. Some studies suggest micronized progesterone and dydrogesterone may carry lower breast cancer risk than synthetic progestins, though more research is needed to confirm this.
How You Take It
Pills: Convenient but processed through your liver first. These are taken daily.
Skin patches or gels: Bypass liver metabolism, potentially reducing blood clot and stroke risk compared to oral forms. These must be applied to an area of the body that other people or pets won’t come into contact with. Usually applied once weekly.
Vaginal creams/tablets: Ideal for localized urogenital symptoms with minimal systemic absorption. Usually applied 2-3 times weekly.
The Critical Role of Timing: When You Start Matters
One of the most important discoveries in menopause medicine is that timing dramatically affects both benefits and risks.
Research on the “timing hypothesis” shows that starting HRT closer to menopause reduces some of the risks seen with later initiation, and leads to more benefits. This finding revolutionized medical thinking about HRT and explains some of the contradictory results from older studies. The FDA used to require its most stringent warning, called a black box warning, on menopausal hormone therapy. In November 2025, the FDA began removing this warning and requested updated labeling from manufacturers, with individual product labels approved after that. The boxed warning for endometrial cancer remains in place on systemic estrogen-alone products. This followed a shift in understanding, as the scientific community came to recognize that earlier interpretations of large studies like the Women’s Health Initiative had overstated the risks of MHT for women starting treatment near menopause.
Benefits of HRT
Reduces Hot Flashes and Night Sweats
HRT is the most effective available treatment for vasomotor symptoms. (1) Studies consistently show it substantially reduces hot flashes and night sweats in most women, leading to better sleep and daily functioning. For many people, the hot flashes and night sweats of menopause are the most disruptive symptoms to daily life.
May Support Brain Function and Mood
Research highlights that the neurological symptoms often associated with menopause like sleep disturbance, “brain fog,” and mood changes significantly impact quality of life, work productivity, and physical health during the menopausal transition. The relationship between estrogen and cognitive function is complex but crucial for many women experiencing mental fatigue, difficulty concentrating, or memory lapses. A systematic review and meta-analysis of over 1 million participants published in 2025 found no association between HRT and the risk of dementia or mild cognitive impairment in either direction — HRT neither increased nor reduced that risk. (4) A pair of smaller 2019 studies suggested that HRT may improve some factors that are tested with baseline cognitive assessments. (2,3) It is unclear if HRT can alleviate the cognitive changes associated with menopause, but this would benefit from further study.
Contributes to Long-Term Survival Benefit
Research tracking over 1,000 women for nearly two decades has been associated with a survival benefit in that population. The graph below shows cumulative survival probability over 18 years, comparing women who used HRT versus those who didn’t:
[image]
Figure adapted from Hodis HN, Mack WJ. Cancer Journal. 2022;28(3):208-223. This survival curve from the Danish Osteoporosis Study shows a statistically significant reduction of cardiovascular disease by 52% after 10 years of randomized hormone replacement therapy relative to no HRT, and reduction by 39% after 16 years of total follow-up.
What this graph shows: The blue line represents women using HRT, while the red dashed line represents women not using HRT. Higher lines mean better survival rates. The separation between the lines demonstrates that women using HRT in this trial had consistently better survival throughout the study period. The vertical dashed line at year 10 marks an important milestone, and the p-values (0.015 and 0.020) indicate these differences are statistically significant, not due to chance. (5)
Preserves Bone Strength
Estrogen deficiency at menopause accelerates bone loss, increasing fracture risk. This decrease in bone density is called osteoporosis or osteopenia, depending on the severity. HRT can contribute to preventing this bone loss and reducing the risk of fractures, particularly in the spine and hip. Hip and spine fractures dramatically impact quality of life in older age. In a single-center study of roughly 200 patients treated between 2014 and 2017, one year after a hip fracture, the mortality rate was 32%, versus 10% for a vertebral fracture. (6) Preventing fractures can contribute to higher quality of life, and to longer life.
May Improve Blood Sugar Control
Evidence suggests HRT can affect glucose control in women with diabetes and may influence diabetes risk in those without the condition. However, experts emphasize that HRT shouldn’t be used solely for diabetes prevention. For women with existing diabetes, treatment decisions should be individualized based on age, metabolic status, and cardiovascular risk factors.
Treats Vaginal and Sexual Problems
Vaginal dryness, painful intercourse, and urinary symptoms like urgency and recurrent UTIs seriously affect many postmenopausal women’s sexual health and quality of life. Low-dose vaginal estrogen is the first-line treatment for these urogenital symptoms, with minimal absorption into the bloodstream. Estriol, a weaker estrogen form, has gained recognition for safely and effectively treating genitourinary symptoms.
Risks of HRT
While people may exaggerate HRT risks, it is important to understand actual risks and discuss them with your doctor. This helps you make informed decisions. All treatment options carry specific benefits and risks that vary by individual situation.
Breast Cancer Risk
This remains the primary concern for most women considering HRT, though the relationship is nuanced:
Estrogen-only therapy (for women post-hysterectomy) appears to carry lower breast cancer risk than combined therapy
Combined therapy (both estrogen and progesterone) risk varies with your baseline risk and specific treatment type.
Progesterone/Progestin type matters: Micronized progesterone and dydrogesterone, which is designed to closely mimic natural progesterone, show lower associated risk than synthetic progestins in observational studies. Progestin refers to synthetic hormones and progesterone refers to natural hormones.
Experts recommend evaluating your baseline breast cancer risk with your healthcare provider before starting HRT and learning about modifiable risk factors that decrease risk regardless of hormone use. The European Society of Endocrinology recommends against combined HRT use in women with current or prior breast cancer. (7)
Heart Disease and Timing
As emphasized earlier, cardiovascular effects depend critically on when you start. Early initiation (before 60 or within 10 years of menopause) has been associated with a lower risk of heart disease. Late initiation has not been associated with the same benefit and may carry increased risk. Experts such as the European Society of Endocrinology strongly advise stopping HRT after a heart attack. (7)
Blood Clots and Stroke
A review of records from 298 million patients across all 50 states, Lebanon, and Saudi Arabia showed a 26% increase in the risk of arterial blood clots with oral estrogen versus vaginal estrogen. (8) However, overall blood clot risk remains rare (fewer than 10 events per 10,000 women) and can be reduced by choosing transdermal forms like patches, creams, and gels over pills. The level of stroke risk associated with HRT depends on when hormone replacement therapy is started. When started more than 10 years after menopause or after age 60, the risk of stroke is increased. When HRT is started younger and within 10 years of menopause, the risk of stroke is not increased by HRT. (9)
Autoimmune Disease
Recent research found modest associations between HRT and rheumatoid arthritis. Current users showed an 18% higher risk compared to non-users, with long-term use (4+ years) showing 19% higher risk. However, the absolute increase remains small. Women with autoimmune susceptibility should discuss individual risk-benefit ratios with their healthcare provider. (10)
Who Should Consider HRT?
HRT may be appropriate for women who:
Have moderate to severe symptoms affecting quality of life
Are younger than 60 or within 10 years of menopause
Have no contraindications
Understand benefits and risks and prefer hormone treatment
Who Should Avoid HRT?
You should not use HRT if you have:
Estrogen-dependent cancers including breast, ovarian, or endometrial (uterine) cancer
History of blood clots, stroke, heart attack
Active liver disease
Unexplained vaginal bleeding
Known or suspected pregnancy
Women with these conditions should explore alternatives with their healthcare provider.
There are other conditions that may place someone at higher risk of negative side effects, such as uncontrolled high blood pressure or high cholesterol. If you’re considering HRT for menopause, check in with your provider to discuss the potential risks and benefits in your unique medical situation.
Making Your Decision
As one major review emphasizes, decisions about menopause therapy should be personalized, considering your symptoms, health status, risk profile, life expectations, and treatment availability and cost.
Your decision should factor in:
How symptoms affect your quality of life
Your age and time since menopause
Personal and family medical history
Baseline cardiovascular and breast cancer risk
Your preferences and values
Healthcare providers and patients can use the extensive HRT research to make informed decisions about symptom management, long-term health, keeping in mind that prevention strategies must be personalized.
FAQs
What is HRT?
Hormone replacement therapy, also called menopausal hormone therapy, supplements the hormones your body stops producing after menopause. Estrogen is the primary hormone replaced. The goal is not to return hormone levels to what they were before menopause, but to help the body find a new balance that controls symptoms without excess health risk.
At what age should you start HRT?
Timing dramatically affects both benefits and risks. HRT may be appropriate for women younger than 60 or within 10 years of menopause. Early initiation has been associated with a lower risk of heart disease, while late initiation has not been associated with the same benefit and may carry increased risk, which is why age and time since menopause matter alongside symptoms.
Do you need progesterone with estrogen?
If you have an intact uterus, yes. Without progesterone or progestin to balance estrogen’s effects, the uterine lining thickens excessively, which raises cancer risk. For women who have had a hysterectomy, estrogen alone is typically prescribed because there is no uterine lining to protect.
Who should not take HRT?
HRT is not appropriate if you have an estrogen-dependent cancer including breast, ovarian or endometrial cancer, a history of blood clots, stroke or heart attack, active liver disease, unexplained vaginal bleeding, or known or suspected pregnancy. Women with these conditions should explore alternatives with their healthcare provider.
The Bottom Line
Research describes HRT as a sex-specific, time-dependent therapy that has been associated with better long-term health outcomes when started near menopause. Whether it is appropriate for any individual, and what her risk profile looks like, is a determination only her provider can make.
Women spend roughly 40% of their lives in postmenopause, and symptoms can substantially impair quality of life. You deserve to live those decades feeling your best, with effective symptom management and optimized long-term health.
The key is working with a knowledgeable healthcare provider who can assess your individual situation, discuss options thoroughly, and support you in making the choice that fits your health profile, symptom severity, and personal values.
If you’re experiencing menopause symptoms, consider connecting with a healthcare provider through Mochi Health to discuss whether hormone therapy might be right for you. Check your eligibility here.
References
Harper-Harrison, G., Shanahan, M. M., & Carlson, K. (2023). Hormone Replacement Therapy. National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK493191/
Gava G, Orsili I, Alvisi S, et al. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina (Kaunas). 2019;55(10):668. doi:10.3390/medicina55100668 | PubMed
Moradi, F., Jahanian Sadatmahalleh, S., & Ziaei, S. (2019). The effect of hormone replacement therapy on cognitive function in postmenopausal women: An RCT. International journal of reproductive biomedicine, 16(12), ijrm.v16i12.3682. https://doi.org/10.18502/ijrm.v16i12.3682
Melville, M., He, L., Desai, R., Nyamayaro, P., Fox, C., & Kothari, K. (2025). Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. The Lancet Healthy Longevity, 6(12). Full text | PubMed (PMID 41448220) — [DOI in the original draft did not resolve; verify against this record]
Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer Journal. 2022;28(3):208-223. doi:10.1097/PPO.0000000000000591 | PubMed
Rizkallah, M., Bachour, F., Khoury, M. E., Sebaaly, A., Finianos, B., Hage, R. E., & Maalouf, G. (2020). Comparison of morbidity and mortality of hip and vertebral fragility fractures: Which one has the highest burden?. Osteoporosis and sarcopenia, 6(3), 146–150. https://doi.org/10.1016/j.afos.2020.07.002 | PubMed
Mary Ann Lumsden, Olaf M Dekkers, Stephanie S Faubion, Angelica Lindén Hirschberg, Channa N Jayasena, Irene Lambrinoudaki, Yvonne Louwers, JoAnn V Pinkerton, Antoan Stefan Sojat, Leonie van Hulsteijn, European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause, European Journal of Endocrinology, Volume 193, Issue 4, October 2025, Pages G49–G81, https://doi.org/10.1093/ejendo/lvaf206
Bartelt, K., Mathur, N., Deckert, J., Little, D., & Higgs, E. (2025). Blood Clot Risk Influenced by Hormone Therapy Administration Route in Women 50 and Older. Epicresearch.org; Epic Research. https://www.epicresearch.org/articles/blood-clot-risk-influenced-by-hormone-therapy-administration-route-in-women-50-and-older
Barcellona, D. (2026). Cardiovascular risk in hormone replacement therapy. Bleeding, Thrombosis and Vascular Biology, 5(1). https://doi.org/10.4081/btvb.2026.411
Guimarães C, Balbinot E, Marçal F, et al. Hormone therapy in menopause increases rheumatoid arthritis risk: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2026;77:152935. doi:10.1016/j.semarthrit.2026.152935 | PubMed
Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Endocrine Practice. 2017;23(7):869-880. doi:10.4158/EP171828.PS | PubMed
Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nature Reviews Disease Primers. 2015;1:15004. doi:10.1038/nrdp.2015.4 | PubMed
Gompel A, Simcock R. Menopausal hormone treatment and breast cancer. Lancet Diabetes & Endocrinology. 2026 Jan 28:S2213-8587(25)00394-8. doi:10.1016/S2213-8587(25)00394-8 | PubMed
Soltani A, Voedisch AJ. A review of estrogens used in menopausal hormone therapy. Current Opinion in Obstetrics & Gynecology. 2026 Feb 2. doi:10.1097/GCO.0000000000001090 | PubMed
Stuenkel CA. Menopause, hormone therapy and diabetes. Climacteric. 2017;20(1):11-21. doi:10.1080/13697137.2016.1267723 | PubMed
FDA labeling change sources cited inline in The Critical Role of Timing: HHS/FDA announcement, Nov 10 2025 | FDA approves labeling changes
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan. Estradiol and progesterone require a written prescription from a licensed provider. Speak with a provider to determine if estradiol or progesterone is appropriate for you. Individual results are not guaranteed and may vary from person to person. All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices.
No in-place disclaimers are required in the body of this post — there is no pricing, no testimonial and no dosing instruction left in it once the changes above are accepted. If any of the products named turn out to be compounded, add the compounded-medications disclaimer to the block above.
Share this post
Menopause
More articles
Read next
For iOS & Android
